Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,645 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Khwaja J, Bomsztyk J, Atta M, Bygrave C, Forbes A, Durairaj S, Fernandes S, Taylor J, Paterson P, Brearton G, Crawley C, Sheehy O, Brown R, Soutar R, Garg M, Rydzewski A, Jamroziak K, Mahmood S, Wechalekar AD. Khwaja J, et al. Among authors: mahmood s. Br J Haematol. 2024 May;204(5):1811-1815. doi: 10.1111/bjh.19286. Epub 2024 Jan 3. Br J Haematol. 2024. PMID: 38171355
A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis.
Ravichandran S, Hall A, Jenner M, Garg M, Kishore B, Lachmann H, Gillmore J, Pitchford A, Oughton JB, Mahmood S, Sachchithantham S, Hawkins P, Brown S, Wechalekar A. Ravichandran S, et al. Among authors: mahmood s. Amyloid. 2023 Sep;30(3):290-296. doi: 10.1080/13506129.2023.2169124. Epub 2023 May 22. Amyloid. 2023. PMID: 37216268 Clinical Trial.
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis.
Bomsztyk J, Ravichandran S, Giles HV, Wright N, Berlanga O, Khwaja J, Mahmood S, Wisniowski B, Cohen O, Foard D, Gilbertson J, Rauf MU, Starr N, Martinez-Naharro A, Venneri L, Whelan C, Fontana M, Hawkins PN, Gillmore JD, Lachmann H, Harding S, Pratt G, Wechalekar AD. Bomsztyk J, et al. Among authors: mahmood s. Blood. 2024 Mar 28;143(13):1259-1268. doi: 10.1182/blood.2023022399. Blood. 2024. PMID: 38194690
Leukaemia cutis with chronic myelomonocytic leukaemia.
Mahmood S, Cooper A, Ireland R, Pocock C. Mahmood S, et al. Br J Haematol. 2009 Nov;147(4):413. doi: 10.1111/j.1365-2141.2009.07683.x. Epub 2009 Apr 13. Br J Haematol. 2009. PMID: 19388939 Free article. No abstract available.
Haematopoietic stem cell mobilisation followed by high-dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma.
Asher S, Shah R, Ings S, Horder J, Newrick F, Nesr G, Kesse Adu R, Streetly M, Trompeter S, Lee L, Wisniowski B, Mahmood S, Xu K, Papanikalaou X, McMillan A, Popat R, Yong K, Sive J, Kyriakou C, Rabin N. Asher S, et al. Among authors: mahmood s. Br J Haematol. 2023 Sep;202(6):1224-1227. doi: 10.1111/bjh.18990. Epub 2023 Jul 24. Br J Haematol. 2023. PMID: 37488061 No abstract available.
Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience.
Nesr G, Shah R, Kyriakou C, Sive J, Popat R, Yong K, Wisniowski B, Xu K, Wechalekar A, Lee L, Ings S, Papanikolaou X, Mahmood S, Mcmillan A, Horder J, Newrick F, Marfil J, Ainley L, Asher S, Cheesman S, Rabin N. Nesr G, et al. Among authors: mahmood s. Leuk Lymphoma. 2023 Jul-Aug;64(8):1465-1471. doi: 10.1080/10428194.2023.2216817. Epub 2023 Jun 1. Leuk Lymphoma. 2023. PMID: 37259553
1,645 results